Pall Corp

Pall — Q3 FY2014 Earnings Presentation

16 slides from Pall's earnings presentation, May 29, 2014

  1. Slide 1: Q3 FY 2014 Financial Results

    Better Lives. Better Planet.SM © 2014 Pall Corporation Q3 FY 2014 Financial Results May 29, 2014 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the third quarter of fiscal year 2014 are preliminary until our Form 10-Q is filed with the Securities and Exchange Commission on or befor

  3. Slide 3: Conference Call Information

    3 Conference Call Information  Dial-In Toll-Free: 855.356.7268 International: 706.634.1981  Replay Toll-Free: 855.859.2056 International: 404.537.3406  Conference ID: 41194239  Internet: www.pall.com/investor

  4. Slide 4: Q3 Overview

    4 Q3 Overview  Solid Q3 performance – Revenue up 7% ex-FX – SG&A down 160 bps – Strong free cash flow conversion  M&A and FX impact on margins  Continued similar end-market trends  Strong order rates On plan for FY14 All remarks in this presentation are on a “Continuing Operations” basis, which

  5. Slide 5: Q3 Financial Summary

    5 $641 $682 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2013 FY 2014 Q3 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 17.4% 17.6% 10.0% 15.0% 20.0% Operat

  6. Slide 6: Q3 Sales by Segment

    6 Life Sciences Consumables $338 +10% Industrial Consumables $266 +1% Industrial Systems $47 -2% Life Sciences Systems $31 +48% 39% 50% 7% 4% Q3 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represent

  7. Slide 7: Q3 Life Sciences Segment Performance

    7 Q3 Life Sciences Segment Performance Dollars in millions excluding FX Life Sciences markets’ consumables sales growth percentages are excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix 0% 30% 60% 54.9% -260 bps 5

  8. Slide 8: Q3 Industrial Segment Performance

    8 Q3 Industrial Segment Performance Gross Margin Segment Margin  Process Technologies consumables: 0%  Aerospace consumables: -13%  Microelectronics consumables: +18% 0% 30% 60% 46.4% -10 bps 46.5% 0% 30% 60% 15.7% +110 bps 14.6% FY 2013 FY 2014 Sales Q3 FY 2014 YoY Change YoY Change Excluding FX

  9. Slide 9: Cash Flow and Working Capital

    9 Cash Flow and Working Capital YTD FY14 YTD FY13(1) Operating Cash Flow 342$ 207$ CapEx (50) (66) Free Cash Flow 292$ 141$ Other Significant Sources/(Uses) of Cash: Proceeds from sale of assets 6$ 537$ Acquisitions of businesses (195) - Dividends (89) (80) Notes Payable 135 10 Stock Buybacks (250)

  10. Slide 10: Acquisition of Filter Specialists, Inc.

    10 Acquisition of Filter Specialists, Inc. Strategic Highlights  Leading supplier of liquid filter bags and other filtration products  Serves the industrial paint, chemical, petrochemical, oil & gas, and food & beverage markets  New applications and technology for core customers Opportunistic and

  11. Slide 11: Appendix

    Better Lives. Better Planet.SM © 2014 Pall Corporation Appendix

  12. Slide 12: Q3 Earnings and FY 2014 Estimates from Continuing Operations Reconciliation

    12 Appendix: Q3 Earnings and FY 2014 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.80$ 0.65$ 3.24$ Discrete Items: ROTC after pro forma tax effect 0.09 0.09 0.24 Tax Adjustments (0.08) - (0.08) Interest Adjustm

  13. Slide 13: Q3 Sales By Market & Technology Reconciliation

    13 Appendix: Q3 Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q3 FY14 Q3 FY14 Estimated Impact of FX Q3 FY14 Estimate Excluding FX Q3 FY13 % Change Excluding FX Consumables Sales: BioPharmaceuticals 235,724$ 2,503$ 233,221$ 208,219$ 12.0% Food & Beverage 46,097 (975) 47,

  14. Slide 14: Q3 Sales By Market & Technology Reconciliation

    14 Appendix: Q3 Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q3 FY14 Q3 FY14 Estimated Impact of FX Q3 FY14 Estimate Excluding FX Q3 FY13 % Change Excluding FX Consumables Sales: Process Technologies 137,348$ (1,872)$ 139,220$ 139,711$ -0.4% Aerospace 54,088 848 53,240

  15. Slide 15: Q3 Orders by Segment Reconciliation

    15 Appendix: Q3 Orders by Segment Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q3 FY14 Q3 FY14 Estimated Impact of FX Q3 FY14 Estimate Excluding FX Q3 FY13 % Change Excluding FX Life Sciences Orders: Consumables 348,610$ 2,168$ 346,442$ 299,278$ 15.8% Systems 28,535 17 28,518 3

  16. Slide 16: Q3 Operating Profit Reconciliation

    16 Appendix: Q3 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q3 FY14 Q3 FY13 Life Sciences segment profit 88,339$ 81,195$ Industrial segment profit 49,350 45,853 Total segment profit 137,689$ 127,048$ General corporate expenses (17,304) (15,172) Operating profit 12

Pall — Q3 FY2014 Earnings Presentation on 6ix